Daniel D. Gretler
Corporate Officer/Principal at Stanford University
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Kryzwicki | M | - |
Stanford University
| 7 years |
| Pin Pin Tea-Mankorn | F | - |
Stanford University
| 10 years |
| John J. Schembri | M | 62 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 years |
| Enrique Zambrano | M | - |
Stanford University
| 7 years |
| Ben Daniel | M | - |
Stanford University
| 1 years |
| Seth Silverman | M | - |
Stanford University
| 5 years |
| Clancey Stahr | M | - |
Stanford University
| 4 years |
| Christopher E Olin | M | - |
Stanford University
| 7 years |
| Nathan Nolop | M | - |
Stanford University
| 11 years |
| Joel Dudley | M | - |
Stanford University
| 4 years |
| Eric Kroll | M | - |
Stanford University
| 2 years |
| Elaine Zelby | F | - |
Stanford University
| 5 years |
| Sahil Bloom | M | - |
Stanford University
| 4 years |
| Iveshu Bhatia | M | - |
Stanford University
| 1 years |
| Jung-il Choi | M | - |
Stanford University
| 6 years |
| Chase Beeler | M | - |
Stanford University
| 5 years |
| John Melas-Kyriazi | M | - |
Stanford University
| 4 years |
| Mada Seghete | F | - |
Stanford University
| 8 years |
| Karen Martell | F | - |
Stanford University
| 4 years |
| Jonathan Hsu | M | - |
Stanford University
| 5 years |
| Artem Barsukov | M | - |
Stanford University
| 3 years |
| Haomiao Huang | M | - |
Stanford University
| 7 years |
| Argyrios Zymnis | M | - |
Stanford University
| 5 years |
| Vic Miller | M | - |
Stanford University
| 4 years |
| Petr Johanes | M | - |
Stanford University
| 12 years |
| Guillaume Horel | M | - |
Stanford University
| 4 years |
| Andreas Eckner | M | - |
Stanford University
| 4 years |
| David McColl | M | - |
Stanford University
| 6 years |
| Forrest White | M | - |
Stanford University
| 5 years |
| Christina Ho | F | - |
Stanford University
| 5 years |
| Leeor Mushin | M | - |
Stanford University
| 2 years |
| Gülin Yilmaz | F | - |
Stanford University
| 4 years |
| Ibrahim Almojel | M | - |
Stanford University
| 6 years |
| Edward Segal | M | - |
Stanford University
| 4 years |
| Artem Trotsyuk | M | - |
Stanford University
| 4 years |
| Haithem Turki | M | - |
Stanford University
| 10 years |
| Alisha Adam | F | - |
Stanford University
| 5 years |
| Kristen Wong | F | - |
Stanford University
| 4 years |
| Wesley Lim | M | - |
Stanford University
| 4 years |
| Lisa Hersch | F | - |
Stanford University
| 2 years |
| Geoffrey Woo | M | - |
Stanford University
| 4 years |
| Sampath Jinadasa | M | - |
Stanford University
| 5 years |
| Rapp Alyssa | F | 45 |
Stanford University
| 2 years |
| Charles Homcy | M | 75 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 14 years |
| Peter Moran | M | - |
Stanford University
| 4 years |
| James Topper | M | 62 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 years |
| Hugh Browne | M | - |
Stanford University
| 2 years |
| R. Lee Douglas | M | 72 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 10 years |
| Jenny P. Chen | F | - |
Stanford University
| 6 years |
| Stephen M. McConnell | M | - |
The University of Chicago
| 1 years |
| Jon Cheek | M | - |
Stanford University
| 7 years |
| Renata Streit Quintini | F | - |
Stanford University
| 4 years |
| Michael Paulus | M | - |
Stanford University
| 5 years |
| Djalil Reghis | M | - |
Stanford University
| 2 years |
| Lou Fernandes | M | - |
Stanford University
| 2 years |
| Manu Lakkur | M | - |
Stanford University
| 5 years |
| James P. McGillicuddy | M | - |
Stanford University
| 5 years |
| Nafis Jamal | M | - |
Stanford University
| 7 years |
| Nathan Evans | M | - |
Stanford University
| 6 years |
| Martin Casado | M | - |
Stanford University
| 6 years |
| Mike Rothenberg | M | - |
Stanford University
| 5 years |
| Sixin Ma | M | 44 |
Stanford University
| 1 years |
| Piotr Andrzej Wianecki | M | - |
Stanford University
| 4 years |
| Robert W. C. Davies | M | 49 |
Stanford University
| 2 years |
| Stephen Westwell | M | 66 |
Stanford University
| 1 years |
| Christopher T. Estreich | M | - |
Stanford University
| 4 years |
| George Y. Sokoloff | M | - |
Stanford University
| 3 years |
| Kirk Wolfe | M | - |
Stanford University
| 2 years |
| David H. Beisel | M | - |
Stanford University
| 2 years |
| Saeko Goto | F | 49 |
Stanford University
| 1 years |
| Rafal Styczen | M | 53 |
Stanford University
| 1 years |
| David S. Glynn | M | - |
Stanford University
| 2 years |
| Rhett Neuenschwander | M | - |
Stanford University
| 2 years |
| Adrian Li | M | - |
Stanford University
| 2 years |
| Hoda Alibair | F | - |
Stanford University
| 2 years |
| Jason Hsiao Chen | M | - |
Stanford University
| 1 years |
| Neil William Flanzraich | M | 80 |
Syntex (USA), Inc.
 Syntex (USA), Inc. Pharmaceuticals: MajorHealth Technology Part of Roche Bay Plc, Syntex (USA), Inc. is a company that manufactures and wholesales pharmaceutical products. The company is based in Palo Alto, CA. | 1 years |
| Lauren Gross | F | - |
Stanford University
| 4 years |
| Daniel Goldberger | M | 65 |
Stanford University
| 1 years |
| Anthony J. Limberis | M | - |
Stanford University
| 2 years |
| Jessica Verrilli | F | - |
Stanford University
| 4 years |
| Paul Strachman | M | - |
Stanford University
| 2 years |
| Thomas P. Chung | M | - |
Stanford University
| 4 years |
| Katia Ameri | F | - |
Stanford University
| 4 years |
| Reda Dehy | M | - |
Stanford University
| 1 years |
| Amr Awadallah | M | - |
Stanford University
| 3 years |
| Carolyn Janiak Earthy | F | - |
Stanford University
| 3 years |
| Kathryn Hume | M | - |
Stanford University
| 5 years |
| Yuval Grill | M | - |
Stanford University
| 2 years |
| Naomi Pilosof Ionita | F | - |
Stanford University
| 2 years |
| Parag Agrawal | M | 40 |
Stanford University
| 3 years |
| Hansae Catlett | M | - |
Stanford University
| 3 years |
| Ethan Bing | M | - |
Stanford University
| 2 years |
| Susan Li | F | 38 |
Stanford University
| 4 years |
| Betty Vo | F | - |
Stanford University
| 4 years |
| Lee Ward | M | - |
Stanford University
| 5 years |
| Meredith Nelson | F | - |
Stanford University
| 4 years |
| Navid Shirazi | M | - |
Stanford University
| 2 years |
| Reshma Karipineni | F | - |
Stanford University
| 2 years |
| Nicholas Hsu | M | - |
Stanford University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel D. Gretler
- Personal Network
